AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$SUPN

Supernus (SUPN) Q3 2026 Earnings Call Transcript

Supernus (SUPN) reported Q3 2026 net sales of $91M, up 12% YoY. Qelbree saw 18% prescription growth and $258M in nine-month net sales. ONAPGO sales rose 27% QoQ to $17.1M. ZURZUVAE sales grew 53% YoY to $42M. GOCOVRI sales reached $43M. The company expects to close its merger with Indivior on November 2, 2026, with combined guidance to be provided in February 2027. Full-year 2026 revenue guidance was raised to $875M-$900M.

Original reporting
finance.yahoo.com
Published Oct 30, 2026, 3:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Supernus (SUPN) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SUPNBullishMed
01

Why it matters

The earnings beat and merger consent provide fresh catalysts for both stocks, likely prompting short‑term buying pressure.

02

Market read

First‑time disclosure of earnings and merger consent makes this article highly relevant for traders targeting biotech and M&A opportunities.

03

What to watch

Potential regulatory scrutiny of the merger and reliance on orphan‑drug exclusivity for ONAPGO.

Relevance 8/10Novelty 8/10Timing: today

Background

Supernus (SUPN) released its Q3 2026 earnings call transcript, reporting record revenue, operating profit, and shareholder approval of its merger with Indivior Pharmaceuticals (INDV).

Company-level read

Ticker impact

$SUPNBullishHigh confidence
Context

Q3 2026 earnings released with record revenue and operating profit; merger with Indivior approved by shareholders.

Expected impact

likely upside as market prices in stronger earnings and merger completion.

Evidence & confidence

First report of earnings and merger consent; material revenue growth and cost synergies disclosed.

$INDVBullishHigh confidence
Context

Indivior shareholders approved the merger with Supernus; combined company expected to have strong cash flow.

Expected impact

potential price lift ahead of merger close on November 2.

Evidence & confidence

First disclosure of merger consent; market will price in anticipated synergies.

Market effects

Sector

Biotech and specialty pharma sector may see broader rally on strong earnings and consolidation.

Regional

U.S. biotech market gains from two mid‑cap players reporting positive results.

Global

Merger adds to global specialty pharma landscape, modest cross‑border impact.

Counterpoint

What could challenge this read

If integration risks materialize, the combined entity could face execution challenges, tempering upside.

Key entities

  • Company
    Supernus Pharmaceuticals

    US‑listed biotech reporting Q3 earnings and merger approval.

  • Company
    Indivior Pharmaceuticals

    US‑listed specialty pharma whose shareholders approved the merger with Supernus.

Read at source← All news

Also covered by

1 outlet

Related articles

$IAMHigh

Bank of America Sees Up to 95% Upside in 2 Stocks

Bank of America analysts see significant upside in Iambic Therapeutics (95%) and Supernus Pharmaceuticals (60%). Iambic's AI-driven cancer treatment IAM1363 showed promising early results, while Supernus's merger with Indivior is expected to drive revenue growth. Both stocks are rated Buy with specific price targets.

finance.yahoo.com
$SUPNMed

Supernus undervalued after Indivior merger, says Bank of America

Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.

finance.yahoo.com
$SUPNHighAI 9/10

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

Supernus Pharmaceuticals (SUPN) and Indivior completed their merger, creating Supernus, Inc. The combined company will trade on Nasdaq under 'SUPN' starting November 3, 2026. The merger enhances financial flexibility, expands the CNS-focused portfolio, and positions the company for long-term growth. Former Indivior shareholders will receive a $1 billion cash dividend, financed by debt and existing cash.

biobuzz.io
$INDVHighAI 8/10

Why Indivior Pharmaceuticals Stock Topped the Market Today

Indivior Pharmaceuticals (NASDAQ:INDV) shares rose 3% on its last day as a standalone company after completing a merger with Supernus Pharmaceuticals (NASDAQ:SUPN). The combined company, to be named Supernus, aims for $125M in annual cost synergies, with Indivior shareholders owning 56.5% of the new entity.

finance.yahoo.com
$SUPNHighAI 8/10

Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals

Supernus Pharmaceuticals (SUPN) completed its merger with Indivior Pharmaceuticals on November 2, 2026, forming Supernus, Inc. The combined company has an 11-product portfolio and headquarters in Rockville, Maryland. Supernus stockholders received 1.5401 Indivior shares per Supernus share. The company borrowed $650 million to fund a $1 billion dividend to Indivior stockholders.

tipranks.com